mRNA non-vaccine therapeutics set to reach $2 billion in sales by 2028

30 November 2022

Although at present there are no messenger RNA (mRNA) non-vaccine therapeutics on the market, this landscape will reach a total of five marketed products by 2028, generating over $2 billion in revenue across the seven major markets (7MM), says data and analytics company GlobalData.

There has been a surge of interest in the mRNA therapeutics space following the COVID-19 pandemic wherein mRNA vaccines proved successful. mRNA is a single-stranded ribonucleic acid that is transcribed from a strand of DNA and carries the coding information for protein synthesis. mRNA therapeutics thus involve the delivery of in-vitro transcribed mRNA into a target cell in order to induce expression of a specific protein, according to GlobalData’s recent report, ‘ mRNA Therapeutics – Thematic Intelligence’.

Among leaders in the field, Moderna (Nasdaq: MRNA), Ultragenyx Pharmaceuticals (Nasdaq: RARE), Omega Therapeutics (Nasdaq: OMGA), and BioNTech (Nasdaq: BNTX) are exploring non-vaccine mRNA therapeutics for cancer and rare genetic diseases.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK